Back to search results

Wearable Activity Trackers for Cancer-Related Fatigue in Pancreatic and Breast Cancer

This study is looking at how well a commercial wearable activity tracker device (WATD) can collect heart rate variability (HRV) data from people with pancreatic or breast cancer who are receiving anti-cancer treatment. Researchers also want to see how acceptable and easy to use the device is for patients. You might be able to join if you are 18 or older, have pancreatic or invasive breast cancer, and are starting or have started anti-cancer treatment. The main goal is to see if people use the device consistently and find it acceptable over 14 days. The current status of this study is unclear, and it plans to enroll 46 participants.

Study design
This is an observational study that plans to enroll 46 participants. It is not specified if this study is randomized or blinded.
What's involved
You would wear a wearable activity tracker device for four weeks, provide experiential diaries, and complete patient-reported outcome (PRO) measures at week two and week four.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for the duration of the four-week study, with adherence and acceptability measured at Day 14.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06291324

WATD and Cancer-Related Fatigue: A Study For Patients Undergoing Anti-Cancer Treatment

Recruiting
Not specifiedAges 18+Observational
Wake Forest University Health Sciences
~46 participants
Updated 2026-07-24 on ClinicalTrials.gov

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Adherence and acceptability
Measured over Day 14

Conditions

Pancreatic Cancer
Breast Cancer

Explore related trials

Breast CarcinomaPancreatic Carcinoma

Where it's being run

1 sites across 1 states
North Carolina1

Study leadership

  • Dori Beeler, PhD · PRINCIPAL_INVESTIGATOR · Wake Forest University Health Sciences

Who to contact

Maggie Dzhanumova
[email protected]
704-754-3768
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Written informed consent and HIPAA authorization for release of personal health information
Patients pancreatic or invasive breast cancer per enrolling investigator who is planning on or has started anti-cancer treatment. Note: Patients with cancer who are not planning to receive anti-cancer treatment are not eligible for study participation
Patients with any severity of self-reported fatigue per enrolling investigator
Age ≥ 18 years at the time of consent
Ability to read and understand the English language
As determined by the enrolling investigator, the ability of the participant to understand and comply with study procedures (i.e., completing questionnaires and device return) for the entire length of the study

Exclusion

Any documented, clinically significant cardiac-related abnormality per enrolling investigator that could compromise the outcome of the study. NOTE: The heart rate data collected using the WATD will not be used for patient care.
Other factors or conditions, per investigator discretion, for which participation in the study would not be in the patient's best interest or could interfere with study assessment results or preclude study completion
No internet, Wi-Fi access or email account
No access to a smartphone or mobile device

What this trial measures

  • Adherence and acceptabilityDay 14

    Adherence is a binary variable and will be determined based on whether the participant uploads HRV data each morning at least 75% of the days during the 14-day trial. Acceptability is a binary variable, and it is based on participant's response to the question whether they find the Wearable Activity Tracker Device (WATD) easy to use in the acceptability survey.